XERS
Xeris Biopharma Holdings, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -11.1% ·
share flow +5.5% ·
net new positions -12.5%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 93 | +3 | 81.56M | $645.48M | +8 | −4 |
| Q1 2026 | 92 | +4 | 77.44M | $449.36M | +7 | −4 |
| Q4 2025 | 88 | +2 | 77.86M | $611.14M | +3 | — |
| Q3 2025 | 17 | 0 | 48.63M | $395.88M | +1 | −2 |
| Q2 2025 | 15 | -1 | 41.39M | $193.31M | — | −1 |
| Q1 2025 | 13 | +3 | 18.95M | $104.02M | +4 | −1 |
| Q4 2024 | 10 | +1 | 14.55M | $49.32M | +1 | — |
| Q3 2024 | 8 | -1 | 9.23M | $26.32M | — | −1 |
| Q2 2024 | 9 | — | 8.75M | $19.69M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 3.33M | +2.9% | $9.50M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 3.33M | +2.9% | $9.50M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Renaissance Technologies ✦ | 1.60M | +18.3% | $4.56M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Millennium Management ✦ | 1.45M | -14.8% | $4.12M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 1.07M | -10.5% | $3.04M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 1.07M | -10.5% | $3.04M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 1.07M | -10.5% | $3.04M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 985.01K | +90.2% | $2.81M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 985.01K | +90.2% | $2.81M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 471.64K | +11.7% | $1.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 471.64K | +11.7% | $1.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Fairfax Financial ✦ | 170.94K | 0.0% | $485,461 | 0.0% | Held | 2 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 160.98K | +22.9% | $459,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Two Sigma Investments | $60,307 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 229 holders, 93.59M shares, $532.36M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 5.00K sh · $42,500
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology